We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.025 | -3.03% | 0.80 | 0.75 | 0.85 | 0.825 | 0.80 | 0.825 | 501,502 | 10:33:59 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.44 | 1.48M |
TIDMN4P
RNS Number : 2412Q
N4 Pharma PLC
25 February 2021
25 February 2021
N4 Pharma plc
("N4 Pharma" or the "Company")
Notice of Annual General Meeting
and
Posting of Annual Report and Accounts
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, announces that the Company's audited accounts for the year ended 31 December 2020, together with the notice of Annual General Meeting ("AGM"), are now available on the Company's website www.n4pharma.com and will be posted to shareholders today.
The AGM will be held at 10.00am on 24 March 2021. In line with current Covid-19 restrictions and in line with the Company's Articles of Association, this year's AGM will be a virtual meeting, full details of which are contained in the notice convening the AGM.
Enquiries:
N4 Pharma plc Nigel Theobald, CEO Via IFC Advisory Luke Cairns, Executive Director SP Angel Corporate Finance LLP Tel: +44(0)20 3470 0470 Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Rob Rees (Corporate Broking) Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657 0050 Joint Broker Andy Thacker/Zoe Alexander IFC Advisory Ltd Tel: +44(0)20 3934 Financial PR 6630 Graham Herring Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ACSSESFILEFSESE
(END) Dow Jones Newswires
February 25, 2021 02:00 ET (07:00 GMT)
1 Year N4 Pharma Chart |
1 Month N4 Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions